logo-loader

Full interview: Hemispherx Biopharma releases 'well tolerated' data for Ampligen ovarian cancer treatment

Published: 23:19 19 Aug 2019 AEST

Hemispherx Biopharma Inc (NYSEAMERICAN:HEB) CEO Thomas Equels tells Protactive that a final report on its phase 1 trial supporting the safety of using its flagship drug Ampligen as a combination therapy to treat recurrent ovarian cancer found that it was “well tolerated."

Equels explains the optimal way to administer Ampligen in ovarian cancer patients is into the intraperitoneal cavity near the tumor site, which has been done, and the company has moved forward with Phase II studies.

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

12 hours, 26 minutes ago